Trials / Unknown
UnknownNCT05889767
Exercise-Induced Gut Permeability in Normal-weight Obesity
Indicators of Gut Permeability in Normal-weight Obesity in Response to Brief, Maximal and Sustained, Submaximal Exercise
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Oklahoma State University · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Exercise acutely increases gut permeability and inflammation, even in healthy populations. However, whether this response differs in groups at-risk for CVD that present with low-grade inflammation (e.g., normal-weight obesity) has yet to be examined. The investigators aim to measure serum indicators of gut permeability in those with normal-weight obesity pre- and post-short, intense exercise and sustained, moderate exercise
Detailed description
The investigator's overall goal is to examine how indicators of gut permeability change in response to exercise in individuals with normal-weight obesity (i.e., normal body mass index \[BMI\] and high body fat percent) relative to those with a normal BMI and low body fat percent and those with a BMI in the obesity range and high body fat percent. The investigators will examine indicators of gut permeability (specified in primary outcomes) in response to a short, intense bout of exercise (i.e., VO2 max test on a cycle ergometer) and sustained, moderate bout of exercise (i.e., 45 minutes at 65% measured VO2 max on a cycle ergometer). Additionally, the investigators will measure basic anthropometrics, blood lipids and glucose, and body composition with DXA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max) | All participants will complete two exercise sessions: 1. VO2 max test on a cycle ergometer 2. Moderate exercise session (45 minutes at 65% measured VO2 max) |
Timeline
- Start date
- 2023-01-10
- Primary completion
- 2023-08-01
- Completion
- 2023-08-01
- First posted
- 2023-06-05
- Last updated
- 2023-06-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05889767. Inclusion in this directory is not an endorsement.